HAE
$60.43+0.73 (+1.22%)
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting sof...
Recent News
Does Haemonetics' (HAE) Hospital Rebound and NexSys Expansion Reframe Its Competitive Positioning?
In recent months, Haemonetics has reported a recovery in its Hospital division, supported by broader adoption of its FDA-approved NexSys PCS system with Persona Technology and the completed transition away from older PCS2 devices. This operational progress, alongside the Attune Medica and OpSens acquisitions that expand its hospital and interventional cardiology offerings, signals a meaningful broadening of the company’s product base despite ongoing debt and competitive pressures. Next,...
Why Is QuidelOrtho (QDEL) Down 24.5% Since Last Earnings Report?
QuidelOrtho (QDEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
2 Healthcare Stocks with Solid Fundamentals and 1 Facing Challenges
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have seen decent returns lately as healthcare stocks were up 3.8% over the past six months, almost identical to the S&P 500.
Why Is Zimmer (ZBH) Down 2% Since Last Earnings Report?
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
HAE's NexSys PCS adoption and hospital recovery signal growth ahead, but a leveraged balance sheet and stiff competition still cloud the stock's outlook.